Navigation Links
PDL BioPharma Announces Two $0.50 Dividends in 2010
Date:1/28/2010

INCLINE VILLAGE, Nev., Jan. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay two special dividends to its stockholders in 2010. Each of the dividends will be $0.50 per share. The first special dividend will be paid on April 1, 2010 to all stockholders who own shares of PDL on March 15, 2010, the Record Date. The second special dividend will be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the Record Date.

Stockholders desiring to purchase shares with rights to the special dividend must ensure that their trades are executed prior to the "ex-dividend" date and settle prior to the Record Date. NASDAQ will establish an ex-dividend date that is generally three business days prior to the Record Date. You should consult with your broker or financial advisor regarding your specific situation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

As all dividend payments are subject to compliance with legal requirements, dividend announcements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2009. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

SOURCE PDL BioPharma

RELATED LINKS
http://www.pdl.com

'/>"/>

SOURCE PDL BioPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
2. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
3. Seven More Biopharmaceutical Research Companies Join PhRMA
4. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
5. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
9. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
10. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
11. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... During the last ... provide free screening colonoscopies to eligible individuals in the local community. , Colon ... but regular screenings can detect colon cancer while it is small, confined and easier ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Full Contact K9, ... of Pet Protect Law that assists dog owners in creating legally-enforceable pet ... owners in taking the natural next step to protect their new companion. Says Evan ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The Global ... Japanese public-private partnership formed to battle infectious diseases ... totaling US$23 million* that could help deliver a ... of debilitating conditions. This latest ... Phase 3 clinical trial testing a pediatric formulation ...
(Date:3/29/2017)... TREE, Colo. , March 29, 2017  Zynex (OTCQB: ... manufacture and sale of non-invasive medical devices for pain ... today that it will host the Company,s 2016 full-year ... a.m. Eastern Time.) The Company expects to ... 31, 2017. ...
(Date:3/29/2017)... 29, 2017  Glenmark Pharmaceuticals, a global pharmaceutical ... an investigational fixed-dose combination of mometasone furoate (25 ... as a nasal spray being studied for the ... from a recently completed Phase 3 trial assessing ... therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology: